4-(2-喹啉-6-基乙炔基)苯胺 | 656820-80-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 4-(2-喹啉-6-基乙炔基)苯胺
• 英文名称: 4-[2-(6-quinolinyl)ethynyl]aniline
• 英文别名: 4-(Quinolin-6-ylethynyl)aniline；4-(2-quinolin-6-ylethynyl)aniline
• CAS: 656820-80-3
• 化学式: C₁₇H₁₂N₂
• 分子量: 244.296
• InChiKey: RKAGWQTYZHVSJW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(2-喹啉-6-基乙炔基)苯胺 在 盐酸羟胺 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 (1S,2S)-Cyclohexane-1,2-dicarboxylic acid 1-hydroxyamide 2-[(4-quinolin-6-ylethynyl-phenyl)-amide]
  参考文献：
  名称：

  Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification

  摘要：

  Rational design based on the broad spectrum MMP inhibitor CGS 27023A led to the identification of a novel series of cyclic succinate TACE inhibitors. As a mixture of two enantiomers, the lead compound 17b exhibited potent enzyme activity (IC50 = 8 nM) in the inhibition of porcine TNF-alpha converting enzyme (pTACE) and excellent selectivity over aggrecanase and MMP-1, -2 and -9. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.056
• 作为产物：
  描述：

  N-Boc-4-碘苯胺 在 盐酸 、 copper(l) iodide 、 四(三苯基膦)钯 、 potassium carbonate 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 为溶剂， 生成 4-(2-喹啉-6-基乙炔基)苯胺
  参考文献：
  名称：

  Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification

  摘要：

  Rational design based on the broad spectrum MMP inhibitor CGS 27023A led to the identification of a novel series of cyclic succinate TACE inhibitors. As a mixture of two enantiomers, the lead compound 17b exhibited potent enzyme activity (IC50 = 8 nM) in the inhibition of porcine TNF-alpha converting enzyme (pTACE) and excellent selectivity over aggrecanase and MMP-1, -2 and -9. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2003.09.056

文献信息

• [EN] IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS<br/>[FR] AGENTS D'IMAGERIE POUR DÉTECTER DES TROUBLES NEUROLOGIQUES
  申请人：SIEMENS MEDICAL SOLUTIONS

  公开号：WO2011119565A1

  公开（公告）日：2011-09-29

  Imaging agents of formulas (I)-(V) and methods for detecting neurological disorders comprising administering to a patient in need compounds of formulas (I)-(V) capable of binding to tau proteins and β-amyloid peptides are presented herein. The invention also relates to methods of imaging Αβ and tau aggregates comprising introducing a detectable quantity of pharmaceutical formulation comprising a radiolabeled compound of formulas (I)-(V) and detecting the labeled compound associated with amyloid deposits and/or tau proteins in a patient. These methods and compositions enable preclinical diagnosis and monitoring progression of AD and other neurological disorders. Formula (V) or a pharmaceutically acceptable salt thereof, and stereoisomers thereof, wherein: X25-X28 are each independently CH, CR11, or N; X29 is CH, N, O or S; X30 is CH, C, or N; X31-34 are each independently CH, CR12, CR13 or N; RII-RU are each independently H, halogen, hydroxy, nitro, cyano, ammo, alkyl, alkylaryl, alkylamino, alkylamine, arylamine, arylamino, alkoxy,— (O-CH2- CH2)n-, alkenyL alkynyl, aryloxy, NRl0COOalkyl, NRl0 COOaryU NRW COalkyl, NR10 CO aryl, COOalkyl, COOaryl, COalkyl, COaryl, aryl, cycloalkyl, cycloalkylamino, cycloalkylamine, bicyclic, saturated heterocycle and unsaturated heterocycle, wherein at least one carbon of R11-R13 is optionally replaced with N, Q, S, triazole, or halo, and, wherein at least one hydrogen is optionally replaced with halo, amine, amino, alkoxy, nitro, alkyl, alkenyL alkynyl, aryloxy, alkylaryl, alkylamino, alkylamine, NRioCOOalkyl, NR10 COOaryl, NR10 COalkyl, NR,0 CO aryl, COOalkyl, COOaryl, COalkyl, COaryl, aryl, cycloalkyl, cycloalkylamino, cycloalkylamine, bicyclic saturated heterocycle and unsaturated heterocycle, a leaving group, CN, OH or a radioactive isotope.
• Rational design, synthesis and structure–Activity relationships of a cyclic succinate series of TNF-α converting enzyme inhibitors. Part 1: lead identification
  作者：Chu-Biao Xue、Xiaohua He、John Roderick、Ronald L. Corbett、James J.-W. Duan、Rui-Qin Liu、Maryanne B. Covington、Robert C. Newton、James M. Trzaskos、Ronald L. Magolda、Ruth R. Wexler、Carl P. Decicco

  DOI：10.1016/j.bmcl.2003.09.056

  日期：2003.12

  Rational design based on the broad spectrum MMP inhibitor CGS 27023A led to the identification of a novel series of cyclic succinate TACE inhibitors. As a mixture of two enantiomers, the lead compound 17b exhibited potent enzyme activity (IC50 = 8 nM) in the inhibition of porcine TNF-alpha converting enzyme (pTACE) and excellent selectivity over aggrecanase and MMP-1, -2 and -9. (C) 2003 Elsevier Ltd. All rights reserved.